Technology
- Home
- > Technology >
- Collaboration
Representative oncology drugs for HCC under clinical trial
| Molecular targeted drug |
Immuno-oncology drug | Cytotoxic drug | Others | |
|---|---|---|---|---|
| TKI | Levantinib | Nivolumab (anti-PD-1) | CBSFlatin (Cisplatin) | JX-594 (virus) |
| Refametinib | Tremelimumab | Thermodox (Doxorubicin) | miR-221 (microRNA) | |
| (anti-CTLA-4) | ||||
| LY2157299 | Livatag (Doxorubicin) | G-202 (peptide) | ||
| Regorafenib | WELCOME ANY CHANCE TO COLLABORATION FOR CO-DEVELOPMENT OF DRUG AND CDx |
|||
| Tivantinib | ||||
| INC280 | ||||
| Cabozantinib | ||||
| Axitinib | ||||
| Erlotinib | ||||
| HDACi | Resminostat | |||
| Belinostat | ||||
WELCOME ANY CHANCE TO COLLABORATION !!
Collaboration advantages
| 1 | KCBC : Network of Hepatologists, Surgeons and Physicians in Korea |
| 2 | Performing biopsy for gene expression analysis in a study trial or routine practice |
| 3 | Much lower budget for a clinical trial in Korea |
| 4 | Our experience in regulatory affairs for approval of in vitro diagnostics and investigational new drug with Korea FDA |
